pomalidomide has been researched along with Kidney Diseases in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Biran, N; Duma, N; Richter, J; Siegel, D; Vesole, DH | 1 |
Abudayyeh, A; Doshi, M; Edeani, A; Glezerman, IG; Jhaveri, KD; Monga, D; Rosner, M; Wanchoo, R | 1 |
1 review(s) available for pomalidomide and Kidney Diseases
Article | Year |
---|---|
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Everolimus; Humans; Imidazoles; Immunologic Factors; Indoles; Kidney Diseases; Lenalidomide; Multiple Myeloma; Nivolumab; Oligopeptides; Oximes; Proteasome Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Thalidomide; Vemurafenib | 2017 |
1 other study(ies) available for pomalidomide and Kidney Diseases
Article | Year |
---|---|
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Humans; Kidney Diseases; Middle Aged; Multiple Myeloma; Oligopeptides; Recurrence; Thalidomide | 2017 |